ODYSSEY ALTERNATIVE ( NCT01709513 ) evaluates efficacy and safety of alirocumab , a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody , in patients with well-documented statin intolerance and moderate to very high cardiovascular risk .